- Home
- SERA vs CRBU Comparison
SERA vs CRBU Comparison
Compare SERA & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERA
- CRBU
- Stock Information
- Founded
- SERA 2008
- CRBU 2011
- Country
- SERA United States
- CRBU United States
- Employees
- SERA N/A
- CRBU N/A
- Industry
- SERA Precision Instruments
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- SERA Health Care
- CRBU Health Care
- Exchange
- SERA Nasdaq
- CRBU Nasdaq
- Market Cap
- SERA 208.7M
- CRBU 236.3M
- IPO Year
- SERA 2021
- CRBU 2021
- Fundamental
- Price
- SERA $6.09
- CRBU $2.00
- Analyst Decision
- SERA
- CRBU Strong Buy
- Analyst Count
- SERA 0
- CRBU 3
- Target Price
- SERA N/A
- CRBU $14.00
- AVG Volume (30 Days)
- SERA 87.1K
- CRBU 1.9M
- Earning Date
- SERA 11-06-2024
- CRBU 11-06-2024
- Dividend Yield
- SERA N/A
- CRBU N/A
- EPS Growth
- SERA N/A
- CRBU N/A
- EPS
- SERA N/A
- CRBU N/A
- Revenue
- SERA $94,000.00
- CRBU $11,475,000.00
- Revenue This Year
- SERA N/A
- CRBU N/A
- Revenue Next Year
- SERA $2,018.04
- CRBU N/A
- P/E Ratio
- SERA N/A
- CRBU N/A
- Revenue Growth
- SERA N/A
- CRBU N/A
- 52 Week Low
- SERA $1.80
- CRBU $1.50
- 52 Week High
- SERA $12.36
- CRBU $8.33
- Technical
- Relative Strength Index (RSI)
- SERA 38.21
- CRBU 42.25
- Support Level
- SERA $5.91
- CRBU $2.37
- Resistance Level
- SERA $6.34
- CRBU $2.08
- Average True Range (ATR)
- SERA 0.65
- CRBU 0.26
- MACD
- SERA -0.17
- CRBU -0.07
- Stochastic Oscillator
- SERA 1.39
- CRBU 3.67
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.